July 2, 2026

Novo Nordisk's Jamey Millar Statement on Wegovy Access Through Medicare Bridge, Pep Club Full-Stack Peptide + Biomarker Telehealth Launch, US News AP Wire on FDA Scientists Warning Against Expanded Peptide Access, PolitiFact Retatrutide Compassionate-Use Primer, Bridge Day 2 Operations

Novo Millar statement on Wegovy Bridge access; Pep Club telehealth launch; US News/AP FDA scientists warning; PolitiFact retatrutide primer; Bridge Day 2.

5 stories · Covering industry, regulatory

Editor's Note

Thursday delivered Day 2 of the Medicare GLP-1 Bridge alongside the mainstream-media aftermath of the FDA staff briefing documents that landed Monday-Tuesday. Novo Nordisk US Operations EVP Jamey Millar released a formal launch statement flagging Wegovy as the only weight-management medicine with cardiovascular-outcome evidence in patients with known heart disease and confirming nationwide availability of all doses and formulations of Wegovy injection and Wegovy pill through the Bridge (PharmExec, PR Newswire). Pep Club, a direct-to-consumer telehealth platform co-founded by Greg Yuna and Gabriella Shak, publicly launched on June 30 pairing prescription therapy and physician-guided peptide protocols with at-home capillary biomarker testing across weight management, hormone optimization, sexual health, hair restoration, skin, IV/vitamin, peptides, and longevity, with licensed-pharmacy fulfillment. US News published an AP wire piece Wednesday July 1 titled 'FDA Scientists Warn Against Expanded Peptide Access As Kennedy Reshapes Advisory Panel,' continuing the mainstream-media coverage of the FDA career-staff briefing documents concluding all seven PCAC peptides have insufficient evidence and the parallel STAT News scoop on the eight new panelists with peptide industry ties. PolitiFact published a primer on retatrutide and compassionate use Wednesday July 1, walking readers through what compassionate use is, what retatrutide is, and the STAT News reporting timeline; the fact-checker did not confirm the patient's identity.

Industry

Novo Nordisk US Operations EVP Jamey Millar Statement (July 1): Wegovy Access Expanded for Medicare Beneficiaries Through the Bridge; All Doses and Formulations of Wegovy Injection and Wegovy Pill Available Nationwide, Company Flags Cardiovascular-Outcome Evidence as Distinguishing Feature for Seniors 65+ with Known Heart Disease

Novo Nordisk US Operations EVP Jamey Millar released a formal statement Wednesday July 1, 2026, framing the Medicare GLP-1 Bridge as 'an important step in getting Wegovy to more patients' and committing to continued work with CMS, healthcare professionals, pharmacists, and patient advocates on Bridge implementation. Millar's cardiovascular-outcome framing was the piece of the statement designed to distinguish Wegovy from competitor GLP-1s under the Bridge: 'Obesity is a serious, common chronic disease facing older Americans, and Wegovy is the only weight management medicine proven to reduce the risk of heart attack, stroke, or cardiovascular death in patients who also have known heart disease. That distinction matters for seniors age 65 and older, who have a high burden of both conditions.' The SELECT trial data (2023-2024) underpin the cardiovascular claim. The Bridge covers all doses and formulations of Wegovy injection (including the 7.2 mg Wegovy HD launched April 2026) and Wegovy pill (1.5, 4, 9, and 25 mg oral tablets, launched January 5, 2026 and reaching 3 million prescriptions by June 7). The program is available nationwide across all US states and territories through December 31, 2027. PharmExec and PR Newswire ran the announcement.

#novo-nordisk #wegovy #medicare-glp-1-bridge #jamey-millar #cardiovascular-outcomes #select-trial #wegovy-pill #wegovy-hd #senior-obesity

Industry

The Pep Club Full-Stack Telehealth Platform Launches Tuesday June 30, 2026 (Co-Founded by Greg Yuna and Gabriella Shak): Prescription Therapy and Physician-Guided Peptide Protocols Paired with At-Home Capillary Biomarker Testing Across Weight Management, Hormone Optimization, Sexual Health, Hair Restoration, Skin, IV/Vitamin Support, Peptides, and Longevity

The Pep Club, a direct-to-consumer telehealth platform co-founded by entrepreneur Greg Yuna (CEO) and Gabriella Shak, publicly launched Tuesday June 30, 2026 at thepepclub.com with a full-stack model pairing prescription medication therapy and physician-guided peptide protocols with at-home biomarker testing. The platform spans more than a dozen categories including weight management (GLP-1 prescriptions), hormone optimization (testosterone, thyroid), sexual health (PT-141, sildenafil, tadalafil), hair restoration (finasteride, GHK-Cu, oral minoxidil), skin and acne (tretinoin, hyaluronic acid, cosmetic peptides), IV and vitamin support, peptides (BPC-157, TB-500, ipamorelin, sermorelin among the compounded offerings), and longevity. All protocols are reviewed and supervised by licensed clinicians and fulfilled through licensed pharmacy partners. The differentiator is the at-home capillary biomarker collection device that lets patients submit lab-quality panels for personalization and monitoring. Yuna, co-founder and CEO: 'When you combine real at-home testing with both prescription and peptide therapy under licensed clinical supervision, you can actually personalize treatment to the individual.' The platform launches into a competitive telehealth market that already includes Hims & Hers, LifeMD, Henry Meds, and Ro; the Pep Club differentiator is the peptide-plus-biomarker integration.

#pep-club #greg-yuna #gabriella-shak #telehealth #biomarker-testing #peptide-therapy #longevity #consumer-launch

Regulatory

US News AP Wire (July 1): 'FDA Scientists Warn Against Expanded Peptide Access As Kennedy Reshapes Advisory Panel': Continuing Mainstream-Media Coverage of the FDA Career-Staff Briefing Documents Released Monday-Tuesday Concluding None of the Seven PCAC Peptides Has Sufficient Evidence for 503A Bulks List

US News, syndicating an Associated Press wire story, published a piece Wednesday July 1, 2026 titled 'FDA Scientists Warn Against Expanded Peptide Access As Kennedy Reshapes Advisory Panel,' continuing the mainstream-media coverage of the FDA career-staff briefing documents that landed Monday-Tuesday June 29-30. The AP framing tied together two threads that STAT News, NBC News, NPR, Washington Post, PBS NewsHour, and CNN had covered separately: the substantive staff position that none of the seven peptides (BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, Epitalon) has sufficient evidence for 503A bulks list eligibility; and the parallel panel-composition story flagging that at least seven of the eight new PCAC panelists named Monday have ties to peptide-related businesses and clinics. The AP wire distribution amplifies the story to hundreds of regional papers and broadcast outlets, extending public awareness well beyond the health-policy audience that read the original STAT scoop. Public Citizen's July 'Outrage of the Month' column, BioCentury's industry-analyst piece, and Personal Care Insights coverage each add to the growing critic chorus three weeks before the July 23-24 PCAC vote.

#fda #pcac #rfk-jr #us-news #ap-wire #peptide-safety #advisory-panel #mainstream-media

Regulatory

PolitiFact (July 1): 'A Primer on Retatrutide and Compassionate Use': Fact-Checker Walks Readers Through What Compassionate Use Is, What Retatrutide Is, the STAT News Reporting Timeline, and What Remains Unconfirmed (Patient Identity, Lilly Rationale, White House Denial Framing)

PolitiFact published a primer piece Wednesday July 1, 2026 titled 'A primer on retatrutide and compassionate use,' laying out the underlying facts of the STAT News June 23 disclosure for readers coming to the story after two weeks of political-controversy coverage. The primer format explained: what compassionate use is (the FDA's expanded-access single-patient IND pathway, 21 CFR 312 Subpart I, ~1,800 requests per year at 99%+ approval); what retatrutide is (Eli Lilly's investigational GLP-1/GIP/glucagon triple agonist, still in Phase 3, TRIUMPH-1 topline 28.3% mean weight loss at 12 mg over 80 weeks); the STAT News reporting timeline (June 23 initial scoop by Lizzy Lawrence, June 25 Senator Hassan letter, June 26 Rep. Ted Lieu press conference, June 29 White House pushback); and what remains unconfirmed (the patient's identity, Lilly's specific rationale for granting the compassionate-use request, whether the White House denial framing constitutes a categorical denial or a non-denial). PolitiFact did not confirm the patient's identity and did not issue a rating on any specific claim; the piece functions as fact-based reference material for the broader public conversation. The primer format is likely to circulate as the reference PolitiFact link for future stories on the case.

#politifact #retatrutide #compassionate-use #eli-lilly #fact-check #trump #hassan-letter #stat-news

Industry

Medicare GLP-1 Bridge Day 2 (Thursday July 2): First-Day Prior-Authorization Submissions Now Flowing Through Humana Central Processor, CMS Targets 72-Hour Turnaround, First Fills Expected the Week of July 6 as Pharmacies Complete Bridge-Specific Billing System Setup Using BIN 028918 / PCN MEDDGLP1BR

Day 2 of the Medicare GLP-1 Bridge demonstration ran through Thursday July 2, 2026 as the first prior-authorization submissions filed on Wednesday July 1 began flowing through Humana as central processor. CMS targets 72-hour turnaround on PA decisions, which puts the earliest Bridge-covered first fills at the pharmacy counter around Thursday July 3 to Friday July 4 for prescriptions submitted Wednesday. The wider first-fill wave is expected the week of July 6 as pharmacies complete Bridge-specific billing system setup using the Bridge BIN 028918 and PCN MEDDGLP1BR identifiers, and as prescribers gain familiarity with the eligibility-attestation workflow (BMI at start of GLP-1 therapy, absence of type 2 diabetes / moderate-to-severe OSA / MASH which would route to standard Part D instead). Humana's parallel role as the Limited Income Newly Eligible Transition (LI NET) program administrator provides operational infrastructure that CMS Medicare Director Chris Klomp cited on the Tuesday launch call as the reason the central-processor model can scale from Day 1 without a ramp-up window. Independent operational tracking through July will indicate whether the 72-hour PA target holds as volume builds.

#medicare-glp-1-bridge #humana #cms #prior-authorization #li-net #chris-klomp #operational-tracking #day-2